The Pharma Data

AUGUST 19, 2021

Under Mr. Gorsky’s leadership, the Company has delivered exceptional financial performance, with its market capitalization growing from nearly $180 billion to more than $470 billion as the share price increased over 170%. “I

Pharmaceuticals 52

Pharmaceuticals Vaccine International Government 52

The Pharma Data

APRIL 25, 2021

In contrast to other options for RSV under development, such as maternal vaccines, nirsevimab was designed to be administered at birth to infants born during the RSV season or at the season’s start for infants born prior to the season. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering.

Virus 40

Virus Trials Disease Hospitals 40

Agency IQ

JUNE 2, 2023

Given the number of approved drugs and biologics on the market that are dispensed on an outpatient basis – and their generic and biosimilar equivalents – the additional workload on FDA’s labeling review staff could be considerable. Some exemptions: Vaccine manufacturers are likely to benefit from the FDA’s proposed rule.

FDA 40

FDA FDA Approval Regulations Production 40

The Pharma Data

MAY 13, 2021

Clients who get results will rave about your skills and nothing beats word of mouth marketing. 2003 ACE Personal Trainer of the Year. ve built a six figure business by providing great service to my clients. This course will help you do that. s a solid investment which will pay for itself in no time. Curb Ivanic, MS, CSCS.

Production 52

Production Treatment Vaccine Research 52

Drug & Device Law

MAY 30, 2022

1981) (applying Virginia law), both of which involved vaccines. In Stanback the prescriber had a similar practice of not warning of a “slight risk,” which led to the same result: [The prescriber] averred that he had not found it necessary and did not make it his practice to advise patients about the risks associated with flu vaccinations.

Testimonials 59

Testimonials Doctors Production Laboratories 59

Drug & Device Law

MARCH 4, 2024

In the middle was In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices. & A Vaccine Act case similarly held that “parties are expected to put their best case forward in the first instance.” March 14, 2003), recognized that replacing an excluded expert “is not the way the Federal Rules of Civil Procedure work.

Testimonials 52

Testimonials Production Vaccine Pharmaceuticals 52

Drug & Device Law

DECEMBER 12, 2022

Some of us on the Blog are veterans of the original vaccine wars – those that preceded the enactment of the Vaccine Act, 42 U.S.C. 223, 231-33 (2011), holding that the Vaccine Act preempted all design defect claims asserted by claimants who rejected Vaccine Act awards and sought to litigate their claims instead.

Vaccine 115

Vaccine Production Hospitals Nurses 115

Drug & Device Law

FEBRUARY 20, 2023

In product liability litigation generally, plaintiffs have been allowed to invent all kinds of “alternative” designs as long as some “expert” opines that the design (even if never before marketed) is “feasible.” Or does it suffice that a vaccine design has been approved in other countries? In Bruesewitz v. Wyeth LLC , 562 U.S.

FDA 59

FDA FDA Approval Testimonials Vaccine 59

Drug & Device Law

JANUARY 4, 2024

The complaint, brought under the Texas consumer protection statute, sued a major manufacturer of COVID-19 vaccine that was used to control the recent pandemic. To the contrary, the COVID-19 vaccine in question was fully approved by the FDA as safe and effective on August 23, 2021, and has remained so (or updated versions have) ever since.

Vaccine 59

Vaccine FDA FDA Approval Pharmacy 59